- Home
- FLGC vs LGVN Comparison
FLGC vs LGVN Comparison
Compare FLGC & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- LGVN
- Stock Information
- Founded
- FLGC 2019
- LGVN 2014
- Country
- FLGC United States
- LGVN United States
- Employees
- FLGC N/A
- LGVN N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- FLGC Health Care
- LGVN Health Care
- Exchange
- FLGC Nasdaq
- LGVN Nasdaq
- Market Cap
- FLGC 15.9M
- LGVN 16.4M
- IPO Year
- FLGC 2021
- LGVN 2021
- Fundamental
- Price
- FLGC $27.89
- LGVN $0.75
- Analyst Decision
- FLGC Strong Buy
- LGVN Strong Buy
- Analyst Count
- FLGC 1
- LGVN 2
- Target Price
- FLGC $156.00
- LGVN $6.50
- AVG Volume (30 Days)
- FLGC 10.2K
- LGVN 452.5K
- Earning Date
- FLGC 11-12-2025
- LGVN 11-11-2025
- Dividend Yield
- FLGC N/A
- LGVN N/A
- EPS Growth
- FLGC N/A
- LGVN N/A
- EPS
- FLGC N/A
- LGVN N/A
- Revenue
- FLGC $52,373,000.00
- LGVN $2,073,000.00
- Revenue This Year
- FLGC N/A
- LGVN N/A
- Revenue Next Year
- FLGC $10.22
- LGVN N/A
- P/E Ratio
- FLGC N/A
- LGVN N/A
- Revenue Growth
- FLGC N/A
- LGVN 68.67
- 52 Week Low
- FLGC $15.15
- LGVN $0.63
- 52 Week High
- FLGC $82.29
- LGVN $2.48
- Technical
- Relative Strength Index (RSI)
- FLGC 55.63
- LGVN 35.29
- Support Level
- FLGC N/A
- LGVN $0.78
- Resistance Level
- FLGC $24.95
- LGVN $0.85
- Average True Range (ATR)
- FLGC 1.32
- LGVN 0.05
- MACD
- FLGC -0.30
- LGVN 0.02
- Stochastic Oscillator
- FLGC 99.96
- LGVN 20.14
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.